Limitations of this study
MM
This was the first study to use geriatric assessment to investigate ICd and Id in elderly frail patients with NDMM. All the enrolled patients in this study were frail (score ≥2), and the results provided evidence for treatment of the elderly and frail patients with NDMM, but there were some limitations in this study. First, the sample size was small and no robust conclusions could be drawn. Second, the follow‐up was short and not sufficient to observe the long‐term outcomes and the prognosis. Third, the number of patients receiving ixazomib for maintenance therapy was small and relevant conclusions could not be drawn. Fourth, generally, gender does not affect the ORR and prognosis of MM, but our data was biased towards female. Whether gender had an effect on the results requires further study. In addition, we could not conclude the effects of cytogenetics, stages and age on the prognosis significantly. Finally, as we mainly assessed patients who received at least two cycles of treatment, there might be some bias. A larger number of patients will be enrolled to further study, which will give a more comprehensive real‐world analysis including the clinical and economic benefits. In brief, we made descriptive statistics for the study due to the small number of patients, and made no more convincing conclusions about the relevance of ICd and Id therapy. Although some results were not statistically significant, this initial study presented a real‐world analysis of the combinations, and the phenomenon between the two groups should not be ignored, which would provide potential clinical information.